More recently, studies have shown that sodium-glucose cotransporter-2 inhibitors (SGLT2-i) may improve cardiac autonomic dysfunction in type 2DM patients, as published in the SCAN Study, which may lead to new research directions toward HF patients [60]. Here, SLC5A2 is linked to hydrops fetalis.